Michael Wagner

Michael Wagner


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
EDElisabeth Defossa
Elisabeth Defossa
MWMichael Wagner
Michael Wagner

5 May 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
THTorsten Haack
Torsten Haack
MLMartin Lorenz
Martin Lorenz
MBMartin Bossart
Martin Bossart
RERalf Elvert
Ralf Elvert
MWMichael Wagner
Michael Wagner

20 March 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
AKAimo Kannt
Aimo Kannt
AMAndreas Nygaard Madsen
Andreas Nygaard Madsen
CKClaire Kammermeier
Claire Kammermeier
RERalf Elvert
Ralf Elvert
TKTim Klöckener
Tim Klöckener
MWMichael Wagner
Michael Wagner

1 April 2019 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
MBMartin Bossart
Martin Bossart
CHChristoph Heubel
Christoph Heubel
USUrsula Stock
Ursula Stock
MWMichael Wagner
Michael Wagner

15 February 2019 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
Irina VelikyanIrina Velikyan
Irina Velikyan
THTorsten Haack
Torsten Haack
MBMartin Bossart
Martin Bossart
AEAndreas Evers
Andreas Evers
ILIina Laitinen
Iina Laitinen
OEOlof Eriksson
Olof Eriksson
The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement. Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat. In in vivo biodistribution, binding specificity and dosimetry were assessed in rat. [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals. [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG receptor occupancy in humans.

5 February 2021 in Diabetes
Verified
Journal Article
Closed access
PDF file
OEOlof Eriksson
Olof Eriksson
IVIrina Velikyan
Irina Velikyan
THTorsten Haack
Torsten Haack
MBMartin Bossart
Martin Bossart
AEAndreas Evers
Andreas Evers
MWMichael Wagner
Michael Wagner
Targeting of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is an emerging strategy in antidiabetic drug development. The aim of this study was to develop a positron emission tomography (PET) radioligand for the GIPR to enable the assessment of target distribution and drug target engagement in vivo. The GIPR-selective peptide S02-GIP was radiolabeled with 68Ga. The resulting PET tracer [68Ga]S02-GIP-T4 was evaluated for affinity and specificity to human GIPR (huGIPR). The in vivo GIPR binding of [68Ga]S02-GIP-T4 as well as the occupancy of a drug candidate with GIPR activity were assessed in nonhuman primates (NHPs) by PET. [68Ga]S02-GIP-T4 bound with nanomolar affinity and high selectivity to huGIPR in overexpressing cells. In vivo, pancreatic binding in NHPs could be dose-dependently inhibited by coinjection of unlabeled S02-GIP-T4. Finally, subcutaneous pretreatment with a high dose of a drug candidate with GIPR activity led to a decreased pancreatic binding of [68Ga]S02-GIP-T4, corresponding to a GIPR drug occupancy of almost 90%. [68Ga]S02-GIP-T4 demonstrated a safe dosimetric profile, allowing for repeated studies in humans. In conclusion, [68Ga]S02-GIP-T4 is a novel PET biomarker for safe, noninvasive, and quantitative assessment of GIPR target distribution and drug occupancy.